Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Recruiting · NCT04919382 · Registry updated 2026-04-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 2 | 2026-04-08 | NCT04919382 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dwight Owen | 3 |
| Genentech, Inc. | 221 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis | United States | 38 |
| Ohio State University Comprehensive Cancer Center | Columbus | United States | 548 |
| University of Illinois Cancer Center | Chicago | United States | 34 |
| University of Iowa Hospitals and Clinics | Iowa City | United States | 99 |
| University of Wisconsin | Madison | United States | 64 |